Share:
SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors. Ms. Romano is the Founder and Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm for global technology companies. As we expanded our Board, we sought a candidate who would help us best serve shareholders as we work towards making new treatments available for patients through the continued advancement of our Phase 2/3 clinical studies for ATH-1017 in Alzheimer s disease, said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. Kelly has a track record of operational success and an aptitude for understanding growing companies as we continue to drive the business forward.